Doppelgänger dilemma: Leiomyoma versus uveal melanoma

Ankit Singh Tomar, Anthony Fam, Paul T. Finger, Codrin E. Iacob

Abstract

Background: Ciliary body tumors can remain undetected and achieve large dimensions. Pigmented ciliary body tumors include: melanoma, leiomyoma and melanocytoma, however correct diagnosis may require tissue diagnosis with immunohistochemical stains.

Case presentation: Two men presented with identical ciliochoroidal tumors. Both had darkly pigmented dome-shaped anterior uveal masses, exudative retinal detachments and transillumination shadowing. Ocular PET-CT imaging revealed that both were metabolically active consistent with a diagnosis of cancer. However, immunohistochemical examination revealed one a leiomyoma and the other melanoma.

Conclusion: Uveal leiomyoma can be an indistinguishable doppelganger to ciliochoroidal melanoma, where the diagnosis can only be established by immunohistochemistry.

Introduction

Uveal leiomyoma is a rare benign tumor of neural crest cell origin which can be clinically indistinguishable from a uveal melanoma. A recent study reviewed 80 published cases of ocular leiomyoma from 1899 to 2019 and found that pigmented cilio-choroidal tumors clinically diagnosed as large uveal melanomas were most commonly treated by enucleation. However, despite confounding clinical similarities, these 2 tumors have very different prognoses. Though both can cause secondary retinal detachment, macular edema and even extracocular extension, leiomyomas are benign tumors which do not metastasize. Herein, we present 2 anterior uveal tumors which are clinically identical. These doppelganger ciliary body lesions highlight that pre-enucleation differentiation may not be possible clinically, the need for a high index of suspicion, and use of histopathology with immunohistochemical analysis to achieve the correct diagnosis.

Case presentation

Two patients presented to us with ciliochoroidal tumors with nearly identical clinical presentation. The first patient was a 30-year-old male referred for evaluation of a ciliary body tumor in his right eye. The second patient was a 45-year-old male with a 3-month history of blurred vision in the left eye and a similar ciliary body tumor with nearly equivalent epidemiologic and clinical features (Table 1).

These 2 tumors had a shared common presentation of a large dome-shaped ciliary body tumor, which was low-moderately reflective on ultrasound-imaging, blocked light transillumination and had associated exudative retinal detachment (Figs. 1 and 2). Based on these clinical findings, both diagnoses were American Joint Committee on Cancer (AJCC) T4 choroidal melanoma extending into the ciliary body. Positron emission tomography computed tomography (PET-CT) staging revealed both tumors to be hypermetabolic (specific uptake value [SUV] range 3.5–4.2 in patient 1 and SUV range 3.7–4.5 in patient 2). Both were greater than SUV 2.5 and thus consistent with malignancy. There was no radiologic evidence of metastatic disease in either patient.

Patient 1 elected for enucleation, and gross examination of the globe revealed a large dark transillumination defect. Globe sectioning revealed a white ovoid solid cilio-choroidal mass measuring 28 mm in largest basal diameter (transverse) and 18 mm in cross-sectional, anteroposterior extension. The underlying sclera was intact, though the ciliary body was deformed by the tumor. Histopathology revealed proliferating spindle mesenchymal cells with cigar-shaped nuclei disposing vesicular chromatin. Mitotic activity was absent. There was <1% nuclear labelling with Ki-67. The tumor cells were immunoreactive to smooth muscle actin. In contrast, these cells were non-reactive to glial fibrillary acidic protein, S-100, Melan-A, HMB-45 and neurofilament protein. This

Keywords:
Leiomyoma
Melanoma
Immunohistochemistry
Benign
Uvea

ARTICLE INFO

Department of Ocular Tumor and Orbital Disease, The New York Eye Cancer Center, New York, NY, USA
The New York Eye and Ear Infirmary of Mount Sinai, New York, NY, USA

* Corresponding author. FACS The New York Eye Cancer Center, 115 East 61st Street, 5th Floor, New York, NY, 10065, USA.
E-mail address: pfinger@eyecancer.com (P.T. Finger).

https://doi.org/10.1016/j.ajoc.2021.101040
Received 26 June 2020; Received in revised form 16 December 2020; Accepted 18 February 2021

Available online 6 March 2021
2451-9936/© 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license.
Herein, we present 2 ciliochoroidal tumors that were clinically indistinguishable from uveal leiomyoma (Table 2 and Fig. 3). No local recurrence or related systemic disease was noted over 4 years follow-up.

Patient 2 requested tumor biopsy. Aspiration cutter-assisted biopsy was used to obtain tissue for both cytopathology and histopathology. Immunohistochemical stains were positive for HMB-45 and Melan-A—confirming the diagnosis of leiomyoma. PET-CT uptake did not help in differentiating leiomyoma from melanoma, but does suggest inflammation and hyper-metabolism in both.

This study suggests that the best way to differentiate between these doppelganger tumors is with a biopsy for immunohistochemical analysis. Biopsy methods include fine needle aspiration biopsy, Finger Iris Incision Technique, transscleral biopsy and enucleation. Aspiration-cutter biopsy through the iris root can provide a minimally invasive, safe method for obtaining sufficient ciliary body tissue for cytology, histopathology, and immunohistochemical analysis.

Uveal leiomyoma will stain positive for α-smooth muscle actin, muscle-specific actin, desmin, h-caldesmon, and vimentin. For both tumors, the treatment choice can be determined by tumor size, location, and secondary ocular complications. Smaller tumors can be cautiously observed or resected en bloc following histopathologic confirmation. There are reports of successful treatment of leiomyoma with radiation. When biopsy proven leiomyomas are too large to treat with globe sparing local resection or radiation therapy, most have been removed by enucleation. Unlike systemic leiomyoma, ocular leiomyoma have inconsistent expression of sex-steroid receptors and the use of hormonal therapy remains unproven.

Herein, we have described 2 clinically indistinguishable ciliochoroidal tumors in men. They had similar pigmented surface appearance through the pupil, secondary retinal detachments, ultrasonographic dome-shape and moderate internal reflectivity. Only an intuitive suspicion or routine tissue biopsy or some new imaging modality will likely improve clinical diagnosis and influence treatment options.

### Patient consent

The patients consented to publication of the case in writing. This report does not contain any personal information that could lead to the identification of the patient. Therefore, these cases conform to the Tenet’s of Helsinki, the Health Insurance Privacy and Portability Act and have been approved for publication by The New York Eye Cancer Center’s IRB and Ethics Committee’s.

### Intellectual property

We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication with respect to intellectual property. In doing so we confirm that we followed the regulations of our institutions concerning intellectual property.
Fig. 1. (A–D): A: A 30-year-old man with nasal ciliary body tumor, B: Note the dysmorphic fovea. C: A 45-year-old man with temporal ciliary body tumor, D: Note the dysmorphic fovea.

Fig. 2. (A–D): A, B: A 30-year-old man with nasal ciliary body tumor. B-scan ultrasound shows a dome-shaped, moderately low reflective choroidal tumor. Note the small secondary retinal detachment adjacent to the tumor. C, D: A 45-year-old man with temporal ciliary body tumor. B-scan shows a dome-shaped, moderately reflective choroidal tumor. Note the secondary retinal detachment adjacent to the tumor.
We further confirm that any aspects of the work covered in this manuscript that has involved human patients has been conducted with the ethical approval of all relevant bodies and that such approvals are acknowledged within the manuscript.

Funding
Dr. Tomar received an ophthalmic oncology fellowship grant to study with Dr. Finger (from The Eye Cancer Foundation).

Declaration of conflict of interest
No conflicting relationship exists for any author.

Acknowledgements
The Eye Cancer Foundation, Inc. (http://eyecancercure.com) supported this research and publication.

Table 2
Comparative pathological and immunohistochemistry features for 2 patients with large cilio-choroidal tumors.

| Feature               | Patient 1                                                                 | Patient 2                                                                 |
|-----------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|
| **Gross Pathology**   | White ovoid solid cilio-choroidal mass                                    | Tissue obtained through aspiration cutter-assisted biopsy                  |
|                       | Large dark transillumination defect                                        |                                                                           |
| **Histopathology**    | Spindle mesenchymal cells                                                  |                                                                           |
|                       | Cigar-shaped nuclei                                                       |                                                                           |
|                       | Vesicular chromatin                                                       |                                                                           |
| **Immunohistochemical stains** | Smooth Muscle Actin (+)  
Gial fibrillary acidic protein (–)  
S-100 (–)  
Melan-A (–)  
HMB-45 (–)  
Neurofilament protein (–) | Malignant melanocytes  
Marked nuclear enlargement  
Vesicular chromatin  
Prominent eosinophilic nucleoli  
Melan-A (+)  
HMB-45 (+) |

Fig. 3. (A–D): A, B: Leiomyoma pathology analysis reveals: 3A (Hematoxylin-Eosin stain, original magnification × 100) shows spindle mesenchymal cells, with cigar-shaped nuclei and vesicular chromatin. 3B Immunohistochemistry of this tumor shows positive immunoreactivity for smooth muscle actin (SMA) (original magnification × 100). C, D: Uveal melanoma pathology reveals: 3C (Hematoxylin-Eosin stain, original magnification × 100) shows histopathologically similar spindle-shaped cells with marked nuclear enlargement and prominent nucleoli. 3D In contrast, immunohistochemistry shows positive immunoreactivity for HMB-45 (original magnification × 100).

References
1. Blodi FC. Leiomyoma of the ciliary body. Am J Ophthalmol. 1950;33(6):939–942. https://doi.org/10.1016/0002-9394(50)91612-6.
2. Tomar AS, Finger PT, Iacob CE. Intraocular leiomyoma: current concepts. Surv Ophthalmol. 2020;65(4):421–437. https://doi.org/10.1016/j.surophthal.2019.12.008.
3. Chiang W-Y, Lin J-W, Yang I-H, Kuo H-K. Posterior choroidal leiomyoma: a rare case report and literature review. APIMS Acta Pathol Microbiol Immunol Scand. 2015;123(6):540–545. https://doi.org/10.1111/apm.12384.
4. Heegaard S, Jensen PK, Scherfig E, Ju Prause. Leiomyoma of the ciliary body. Report of 2 cases. Acta Ophthalmol Scand. 1999;77(6):709–712.
5. Kim JM, Hall LB, Elia M, Ehrlich MS, Materin MA, Sinard JH. Acute presentation of mesectodermal leiomyoma of the ciliary body. Ocul Oncol Pathol. 2017;3(4):304–309. https://doi.org/10.1159/000464466.
6. Kivelä T, Simpson ER, Gronniklaus HE, et al. Uveal melanoma ophthalmic sites. In: Amin M, Edge SB, Greene FL, et al., eds. The AJCC Cancer Staging Manual. eighth ed. New York: Springer; 2017.
7. Finger PT, Latkany P, Kurli M, Iacob C. The Finger iridectomy technique: small incision biopsy of anterior segment tumours. Br J Ophthalmol. 2005;89(8):946–949. https://doi.org/10.1136/bjo.2004.062553.
8. Razzaq I, Semenova EA, Marinikovic M, de Keizer RJW, Van Duinen SG, Luypen GPM. Mesectodermal supravalve iridociliary leiomyoma: transscleral excision without postoperative iris defect. Arch Ophthalmal Chie Ill. 1960;129(12):1635–1637. https://doi.org/10.1001/archophthalmol.1961.342.
9. Qubill H, Remite IG, Rundle PA, Mudhar HS. Three cases of intracocular mesectodermal leiomyoma expressing progesterone and androgen receptors. Eye Land Engl. 2013;27(5):669–672. https://doi.org/10.1038/eeye.2013.37.
10. Kiss S, Gragoudas ES, Dryja TP, Jakobiec FA. Response of choroidal leiomyoma to treatment with proton beam radiation. *Retin Cases Brief Rep*. 2010;4(2):168–173. https://doi.org/10.1097/ICB.0b013e3181e7d066.

11. Kiratli H, Agan A, Onder S. Ciliary body mesectodermal leiomyoma diagnosed by fine needle aspiration biopsy. *Ocul Oncol Pathol*. 2017;3(3):199–203. https://doi.org/10.1159/000454863.

12. Jakobiec FA, Witschel H, Zimmerman LE. Choroidal leiomyoma of vascular origin. *Am J Ophthalmol*. 1976;82(2):205–212. https://doi.org/10.1016/0002-9394(76)90419-0.

13. Shields JA, Shields CL, Eagle RC, De Potter P. Observations on seven cases of intraocular leiomyoma. The 1993 Byron Demorest Lecture. *Arch Ophthalmol Chic Ill*. 1960;112(4):521–528. https://doi.org/10.1001/archophthalm.1994.01090160097028.

14. Rishi P, Dhami A, Biswas J. Biopsy techniques for intraocular tumors. *Indian J Ophthalmol*. 2016;64(6):415–421. https://doi.org/10.4103/0301-4738.187652.

15. Finger PT, Chua MR, Iacob CE. Micro-incision, trans-iridal aspiration cutter biopsy for ciliary body tumours. *Can J Ophthalmol J Can Ophtalmol*. Published online September. 2020;10. https://doi.org/10.1016/j.jcjo.2020.08.002.

16. Eide N, Farstad IN, Reger M. A leiomyoma of the iris documented by immunohistochemistry and electron microscopy. *Acta Ophthalmol Scand*. 1997;75(4):470–473.

17. Koletsa T, Karayannopoulou G, Drekli D, Vasilieidis I, Papadimitriou CS, Hytiroglou P. Mesectodermal leiomyoma of the ciliary body: report of a case and review of the literature. *Pathol Res Pract*. 2009;205(2):125–130. https://doi.org/10.1016/j.prp.2008.06.004.

18. American Brachytherapy Society - Ophthalmic Oncology Task Force. Electronic address: paulfinger@eye Cancer.com, ABS–OOTF Committee. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. *Brachytherapy*. 2014;13(1):1–14. https://doi.org/10.1016/j.brachy.2013.11.008.